Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03833934 · OUTCOME

Overall Prevalence of ALK Resistance Mechanism Among Patients With the ALK Fusion

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance · Source last updated 2025-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
32 months

What was measured

To determine the overall prevalence of ALK resistance mechanism in patients with detectable ALK fusion in plasma as determined per plasma NGS

Analysis population: Patients with detected ALK fusion

Groups in this outcome

ALK-positive NSCLC With Progression

Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ALK-positive NSCLC With Progression27

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ALK-positive NSCLC With Progression17Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        17
denoms
  1. counts
    1. group Id
      OG000
      value
      27
    units
    Participants
description
To determine the overall prevalence of ALK resistance mechanism in patients with detectable ALK fusion in plasma as determined per plasma NGS
groups
  1. description
    Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)
    id
    OG000
    title
    ALK-positive NSCLC With Progression
param Type
COUNT_OF_PARTICIPANTS
population Description
Patients with detected ALK fusion
reporting Status
POSTED
time Frame
32 months
title
Overall Prevalence of ALK Resistance Mechanism Among Patients With the ALK Fusion
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice